Positive results from phase 2 WILLOW Study of brensocatib in patients with non-cystic fibrosis bronchiectasis presented at conference

RCT (n=256; ≥2 pulmonary exacerbations in previous year) of this oral, reversible inhibitor of dipeptidyl peptidase I met its primary endpoint, with prolongation of time to first exacerbation over 24-week treatment period vs. placebo (p=0.027 for 10mg and p=0.044 for 25mg dose).

Biospace Inc.